Rapport Therapeutics has derived what it believes is 'unprecedented' early efficacy for its precision neuroscience treatment in focal onset seizures - its confidence comes from a unique trial design

CEO Abe Ceesay describes Rapport's precision neuroscience approach of targeting the AMPA receptor specifically through TARPγ8, and explains why the company took the extra step of tracking an electrographic biomarker in its phase 2a study in addition to seizure frequency. Plus, next steps and additional indications.